Last reviewed · How we verify

NCT04327427

Outcome Analysis of Aspirin in Liver Transplantation

Status unknown Last updated 31 March 2020
What this trial tests

trial testing Aspirin in Liver Transplant; Complications in 3,000 participants. Status unknown.

Timeline
1 October 2019
Primary endpoint
1 October 2020
31 May 2021

Quick facts

Lead sponsorUniversity of Zurich
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment3,000
Start date1 October 2019
Primary completion1 October 2020
Estimated completion31 May 2021
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

University of Zurich

Who can join

18 and older, any sex, with Liver Transplant; Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the experimental setting inhibition of platelet activation was able to reduce immune-mediated necroinflammatory liver disease and consecutively hepatocellular carcinoma development. Therefore, antiplatelet therapy may not only have a preventive effect on hepatic artery patency but also on tumor recurrence. So far and to the best of our knowledge, no study investigated the effect of antiplatelet therapy on hepatic arterial patency, tumor recurrence and graft survival after primary liver transplantation.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Low-dose aspirin confers protection against acute cellular allograft rejection after primary liver transplantation.
    Oberkofler CE, Raptis DA, Müller PC, Sousa da Silva RX, et al · · 2022 · cited 13× · PMID 35735232 · DOI 10.1002/lt.26534
  2. Aspirin in hepatocellular carcinoma: Is it an out-of-date or promising treatment?
    Qiu X, Gao F, Wang K, Zhang Z, et al · · 2022 · PMID 40636145 · DOI 10.1016/j.iliver.2022.03.003

Verify or expand the search:

Other trials of Aspirin

Trials testing the same drug.

Other recruiting trials for Liver Transplant; Complications

Currently open trials in the same condition.

Other University of Zurich trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04327427.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing